Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from AFT Pharmaceuticals Ltd. ( (AU:AFP) ) is now available.
AFT Pharmaceuticals has launched its intravenous pain relief medicine, Maxigesic IV, in Canada under the brand name Combogesic IV, as part of its strategy to expand in North America. This move aligns with Canada’s efforts to find non-opioid pain management solutions amidst an ongoing opioid crisis. Additionally, AFT has extended its licensing agreement with Hikma Pharmaceuticals in the US to enhance the commercial reach of its pain relief products, aiming to capitalize on the US market’s demand for non-opioid alternatives.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals Ltd is a New Zealand-based company operating in the pharmaceutical industry. It focuses on developing and commercializing a range of pharmaceutical products, including pain relief medications. The company is expanding its market presence in North America and other international territories, leveraging its patented formulations.
Average Trading Volume: 3,076
Technical Sentiment Signal: Sell
Current Market Cap: A$263M
For detailed information about AFP stock, go to TipRanks’ Stock Analysis page.